Illumina has recently advanced its plan to divest its cancer-diagnostics unit, a move intended to ease regulatory pressure and sharpen its focus on core DNA sequencing and microarray technologies.

Integrated software, AI-driven analytics, and frictionless workflows enable customers to harness the full power of biological insights SAN DIEGO, Jan. 6, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ...

New York Post may receive revenue from affiliate and advertising partnerships for sharing this content and/or when you make a purchase. Once I hit middle age, I became ruthless about preserving the ...

The latest announcement is out from Illumina ( (ILMN)). On November 10, 2025, Illumina, Inc. announced it had entered into an Underwriting Agreement with Goldman ...

Illumina exhibits better profitability ratios than many of its peers, which indicates that the company could continue to invest in its operations. In Q3 2025, ILMN raised its EPS to $4.65-$4.75, ...

Oct 21 (Reuters) - Biotech company 10x Genomics (TXG.O), opens new tab filed two lawsuits against rival Illumina (ILMN.O), opens new tab in Delaware federal court on ...

"Illumina has inflicted substantial harm on Element, resulting in lost sales, diminished market share, and reduced profits," counsel for DNA-sequencing company Element Biosciences Inc. alleged in an ...

Illumina is diving deeper into proteomics research with a $425 million plan to acquire SomaLogic, including its protein analysis platforms and certified lab services business. The deal with ...

Illumina announced today it has entered into a definitive agreement with Standard BioTools under which Illumina will acquire SomaLogic, a leader in data-driven proteomics technology, for up to $425 ...

Just two months after announcing it would be laying off dozens of its San Diego employees, gene sequencing giant Illumina said it plans let go of 172 more workers. In paperwork filed last week with ...

Business: Illumina provides sequencing-and array-based solutions for genetic and genomic analysis. It offers products and services to customers in a range of markets, enabling the adoption of genomic ...